


### Amendments to the Claims:

The listing of claims below will replace all prior versions and listings of claims in the application:

#### Listing of Claims:

1. (Currently amended) 1-Aziridino-1-hydroxyiminomethyl derivatives of the formula I



wherein

R is selected from the group consisting of a single bond and ~~a linker moiety~~ an organic residue capable of bonding covalently two aziridine oxime groups,

R<sub>1</sub> and R<sub>2</sub> independently of one another are selected from the group consisting of -H, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -CN, -COOH, -COOCH<sub>3</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -CONH<sub>2</sub>, or -C<sub>6</sub>H<sub>5</sub> group, provided that each of R<sub>1</sub> and R<sub>2</sub> are is not both -H and ~~provided that R<sub>1</sub> is not -H if R<sub>2</sub> is -CH<sub>3</sub> and R<sub>1</sub> is not or -CH<sub>3</sub> if R<sub>2</sub> is -H,~~ when R is a bond and n is 2.

2. (Currently amended) The compound of claim 1, wherein R is ~~a linker moiety that is a divalent radical~~ an organic residue, derived from a molecule, selected from the group consisting of linear or branched, saturated or unsaturated alkanes or heteroalkanes with up to 6 carbon atoms and with up to four hetero atoms, and C<sub>3</sub>-C<sub>8</sub> cycloalkanes, that are optionally substituted with lower C<sub>1</sub>-C<sub>6</sub> alkyl, lower C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro, amino, monosubstituted amino or halogen groups, heterocyclic compounds with 3 to 6 ring atoms and up to four hetero atoms, aromatic compounds with up to 8

ring atoms, optionally substituted with cyano, hydroxy, lower C<sub>1</sub>-C<sub>6</sub> alkyl, lower C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro, amino, monosubstituted amino, trihaloalkyl and/or halogen groups, and heteroaryls with 3 to 7 ring atoms and up to four hetero atoms.

3. (Currently amended) The compound of claim 2, wherein ~~R is a linker moiety that is a divalent radical~~, the organic residue is derived from a molecule, selected from the group consisting of methane, ethane, propane, butane, isobutane, pentane, isopentane, neopentane, hexane, azine, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, pyrrole, pyrroline, imidazole, imidazoline, pyrazolidine, thiazole, thiazoline, thiazolidine, isothiazole, isothiazoline, isothiazolidine, benzothiazole, furan, dihydrofuran, tetrahydrofuran, benzofuran, thiophene, benzothiophene, oxazole, oxazoline, oxazolidine, piperidine, piperazine, pyrimidine, morpholine, dihydropyran, tetrahydropyran, pyridazine, benzene, furoxane, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, pyridine and pyridine N-oxide, dihydropyridine, pyrimidine, or pyrazine.

4. (Currently amended) The compound of claim 1, wherein R<sub>1</sub> and R<sub>2</sub> independently of one another are selected from the group consisting of -H and -CONH<sub>2</sub>, provided that each of R<sub>1</sub> and R<sub>2</sub> are is not both -H when R is a bond and n is 2.

5. (Currently amended) The compound of claim 1 selected from the group consisting of  
2,6-bis(1-aziridino-1-hydroxyiminomethyl)pyridine,  
1,4-bis(1-aziridino-1-hydroxyiminomethyl)benzene,  
1,4-di( $\alpha$ -2-carbamoylaziridino- $\alpha$ -hydroxyiminomethyl)benzene,  
1,3-bis(1-aziridino-1-hydroxyiminomethyl)benzene,  
~~1,3,5-tris(1-aziridino-1-hydroxyiminomethyl)benzene,~~

1,3-di( $\alpha$ -2-carbamoylaziridino- $\alpha$ -hydroxyiminomethyl)benzene,  
2,6-di( $\alpha$ -2-carbamoylaziridino- $\alpha$ -hydroxyiminomethyl)pyridine,  
3,5-bis(1-aziridino-1-hydroxyiminomethyl)pyridine,  
2,5-bis(1-aziridino-1-hydroxyiminomethyl)pyridine,  
2,4-bis(1-aziridino-1-hydroxyiminomethyl)pyridine,  
2,5-bis(1-aziridino-1-hydroxyiminomethyl)furan,  
3,4-bis[(aziridiny)-1-hydroxyiminomethyl]furoxane,  
bis(2-methoxycarbonylaziridino)glyoxime,  
bis(2-carbamoylaziridino)glyoxime,  
2,2'-azinobis(1-aziridino-1-hydroxyiminomethyl)propane, and  
2,2'-azinobis[1-(2-carbamoylaziridino)-1-hydroxyimino]propane.

Claims 6-8 (Canceled).

9. (Currently amended) A method of treating tumors of or cancerous diseases of at least one of colon, stomach, lung, breast and uterus in humans which comprises administering to a human patient in need of treatment a therapeutically effective amount of a compound of claim 1.

10. (Previously presented) The method of claim 9 wherein said compound is 1,1'-[1,2-bis(hydroxyimino)-1,2-ethanediyl]bisaziridine.

Claim 11 (Canceled).

12. (Previously presented) The compound of claim 2 wherein said C<sub>3</sub>-C<sub>8</sub> cycloalkanes are substituted with at least one substituent selected from the group consisting of lower C<sub>1</sub>-C<sub>6</sub> alkyl, lower C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro, amino, monosubstituted amino, and halogen groups.

Claims 13-14 (Canceled).